On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the treatment of adult patients with hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer that harbors an ESR1 mutation.

This approval represents a significant step forward in targeted cancer therapy, offering a new treatment option for patients with this specific genetic profile. The decision was based on clinical data demonstrating the efficacy of Etcamah combined with CDK4/6 inhibitors in this patient population.

The FDA's approval includes the publication of the approval letter and the official label as of the date of announcement. Healthcare professionals are encouraged to review this information to understand the appropriate use of Etcamah in clinical settings.